Botanical Drug Market Size, Share, Growth, Trends, Global Industry Analysis By Type (Prescription Drug and OTC), By Application (Cardiovascular, Tumor, Respiratory System, and Others), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

BOTANICAL DRUG MARKET OVERVIEW

The global botanical drug market was valued at USD 37.5 billion in 2024 and is expected to grow to USD 39.38 billion in 2025, reaching USD 58.01 billion by 2033, with a projected CAGR of 5% from 2025 to 2033.

Drugs that are derived from medicinal plants are known as botanical drugs. A botanical drug is intended to diagnose, mitigate, cure, prevent, or treat diseases in humans. It consists of vegetable materials. Also, it may include plant materials, macroscopic fungi, algae, or various combinations. Further, chemical purified from plants, such as paclitaxel or artemisinin, and highly purified products of industrial fermentation such as biopharmaceuticals are not considered botanical drug products.

Growing government initiatives are expectedto drive botanical drug market. Further, significant attention to herbal medicines is predicted to increase market demand. Increasing government investments in herbal medicine is projected to drive market growth. In addition, the limitations associated with manufacturing of conventional drugs is another factor to drive market growth in the coming years. Low capital investments and need for low technical expertise are supporting the demand for botanical drug. Increasing focus on development of new drugs in the healthcare sectors  is projected to drive market demand.

BOTANICAL DRUG MARKET KEY FINDINGS

• Market Size and Growth: Approximately 800 botanical IND and pre IND submissions had been received by FDA by 2018, indicating robust research activity.

• Key Market Driver: 88 % of WHO Member States report therapeutic use of herbal medicines, reflecting broad global integration of botanicals in health systems.

• Major Market Restraint: Only four botanical drug products have cleared FDA approval pathways (NDA/BLA), highlighting stringent regulatory challenges.

• Emerging Trends: The FDA Botanical Review Team leverages 100 % of prior human experience data for safety bridging in IND submissions, enhancing development efficiency.

• Regional Leadership: China’s TCM network comprises 65 809 medical institutions as of 2019, up 41.4 % over five years, positioning China as a dominant botanical drug hub.

• Competitive Landscape: Buchang Pharmaceuticals fields 35 traditional Chinese medicine candidates within a 214 product new drug pipeline, reflecting intensive R&D focus on botanicals.

• Market Segmentation: Botanical drug submissions split across NDA (3 products) and BLA (1 product) pathways, with 75 % of approvals under small molecule NDA routes.

COVID-19 IMPACT

Growing Respiratory Problems Among Patients To Accelerate Market Growth

COVID-19 pandemic led people to seek alternative treatments from botanical drugs. To avoid respiratory problems, patients started consuming herbal medicines. During pandemic medicinal plants witnessed a sudden demand. These herbal medicines play a crucial role in preventing or treating respiratory symptoms.  Old aged population used botanical drugs to keep themselves safe from COVID-19 propelled the market growth.

On the contrary, lack of awareness of medicinal plants restricted market growth during the pandemic. Further,  highly educated popularion understood  less about botanical drug treatment. In addition, presence of alternative medicines slowed down the market growth during pandemic. Lockdown restrictions impacted production units and supply chains, which affected the economy as well.

LATEST TRENDS

Growing Government Initiatives to Boost Market Growth

Governments globally have made substantial research investments in herbal medicines that are  predicted  to drive botanical drug market growth. Herbal medicines are witnessing significant demand in the healthcare sector. Botanical drugs are derivatives of medicinal plants, and  they are used in treatments. Further,  increasing government initiatives for the use and approval of botanical drugs are expected to drive product demand. Low capital investments and less need for technical expertise are expected to fuelmarket growth. In addition, growing government investments in herbal medicines is anticipated to boost market growth during the forecast period.

• According to the U.S. Food and Drug Administration, to date four botanical drug products have met the Botanical Guidance definition and been approved under NDA or BLA pathways.

• According to the U.S. FDA’s 2015 draft guidance summary, by 2018 the Agency had received approximately 800 pre IND meeting requests and IND submissions for botanical research.

Request a Free sample to learn more about this report

BOTANICAL DRUG MARKET SEGMENTATION

By Type

Based on type, the market is divided into prescription drug and OTC.

Prescription drug is the leading part of  segmentation type.

By Application

Based on the application, the market is divided into cardiovascular, tumor, respiratory system, and others.

Cardiovascular is the leading part of application segemtation

DRIVING FACTORS

Growing Adoption of Plant-Based Drugs in Medical Sectors to Drive Market Growth

Increasing adoption of herbal medicine globally is expected to drive market growth. Low cost of herbal drugs compared to specialty drugs is expected to propel the growth of the market. Further, technological advancements in manufacturing equipment for botanical drugs are anticipated to increase herbal medicine demand. Growing adoption of  botanical drug in dermatology is due to increasing prevalence of skin disorders. rising need for effective drugs for chronic disorder treatment such as diabetes and cancer is projected to fuel herbal medicine adoption. In addition, increasing herbal drug manufacturing companies globally is projected to fuel market growth during the forecast period. 

Increasing Need for Treatment to Develop Market Growth

Botanical drug help in the treatment of various diseases such as infectious diseases, nervous system disorders, cardiovascular diseases, and respiratory diseases. Herbal medicine is available in multiple forms, such as tablets, pills, and injections. Further, increasing demand for treatments is projected to drive botanical drug market growth. The production process is shorter as compared to conventional drugs. In addition, raw materials used in botanical drugs are easily transported to local facilities. These factors are responsible for accelerating market growth during the forecast period.

• According to World Health Organization estimates, 88 % of all countries make therapeutic use of practices such as herbal medicines, signalling widespread acceptance of botanical interventions.

• According to the FDA Botanical Review Team, robust prior human use data—such as annual sales volumes and exposure populations—can support IND submissions for botanicals, leveraging 100 % of available marketing history information for safety justification.

RESTRAINING FACTORS

Low Acceptance of Herbal Medicine Among Physicians to Restrict Market Growth

Low acceptance of botanical products among physicians is expected to restrict market growth. Many physicians have recommended diabetic patients to consume herbal medicines, which is anticipated to hamper the development of the botanical drug market.

• According to the FDA, only four botanical drug products have successfully navigated the NDA/BLA approval process since the pathway’s inception in 2004, reflecting high technical and regulatory hurdles.

• According to FDA guidance (21 CFR 314.430), manufacturing and supplier information in approved NDAs is considered proprietary and not publicly released, limiting transparency for follow on research.

• Request a Free sample to learn more about this report

•  

BOTANICAL DRUG MARKET REGIONAL INSIGHTS

North America is expected to witness the highest botanical drug market share due to increasing prevalence of chronic diseases. Growing awareness of herbal medicine in the healthcare sector is anticipated to increase market demand. Technological advancements in production process is expected to boost market growth during the forecast period. Further, increasing population and rising awareness of plant-derived drugs are expected to grow market share during the forecast period.

 Asia Pacific is expected to witness significant market growth during the forecast period due to the growing applications of botanical drug. Further, growing prevalence of diseases is anticipated to escalate the adoption of botanical drugs.

Europe is expected to witness considerable market growth due to the increasing government initiatives to support herbal medicine. Further, growing investments by various governments in the region is boosting market growth. In addition, the presence of drug manufacturing companies is one of the factors that is expected to propel the growth of the botanical drug market.

KEY INDUSTRY PLAYERS

Leading Players Adopt Partnership Strategies to Stay Competitive

The report covers information about the list of market players and their latest development in the industry. The information includes mergers, partnerships, acquisitions, technological developments, and production lines.

• Buchang Pharmaceuticals (China): According to Buchang’s R&D Center, the company has 214 new drug varieties under development—including 35 traditional Chinese medicines—across its global facilities.

• China TCM (China): According to China’s National Administration of Traditional Chinese Medicine, the number of TCM medical institutions reached 65 809 by end 2019—a 41.4 % increase since 2015—underscoring the scale of domestic botanical drug infrastructure.

Other aspects examined for this market include complete research on companies producing and introducing the latest products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.

List of Top Botanical Drug Companies

• Buchang Pharmaceuticals (China)
• China TCM (China)
• Tsumura (Japan)
• Schwabe (Germany)
• Tong Ren Tang (China)
• Jumpcan Pharmaceutical (China)
• Guangzhou Baiyunshan Pharmaceutical (China)
• Yunnan Baiyao (China)
• Tasly Holding Group (China)
• Bionorica Se (China)
• Huarun 999 (China)
• Taiji (China)
• Weleda (Switzerland)
• Kwangdong (China)
• GW Pharmaceuticals (U.K.)

INDUSTRIAL DEVELOPMENT

July 2021 – American Herbal Pharmacopoeia (AHP) and the American Botanical Council (ABC) have entered into a partnership. This partnership is aimed at helping the dietary supplement sector.  

REPORT COVERAGE

This research profiles a report with general studies that explain the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by examining the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, and others. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.